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Diabetic retinopathy and diabetic nephropathy are common
microvascular complications of diabetes. The kallikrein–kinin
system (KKS) has been implicated in the development of
both conditions, and, in particular, bradykinin and its
receptors have been shown to exert angiogenic and
proinflammatory actions. Several of the key processes that
underlie the development of diabetic retinopathy, such as
increased vascular permeability, edema, neovascularization,
and inflammatory changes, have been associated with
the KKS, and recent work has shown that components of
the KKS, including plasma kallikrein, factor XIIa, and
high-molecular-weight kininogen, are present in the vitreous
of people with diabetic retinopathy. The role of the KKS in
the development of diabetic nephropathy is controversial,
with both adverse and protective effects of bradykinin and its
receptors reported. The review examines the role of the KKS
in pathways central to the development of diabetic
retinopathy and compares this with reported actions of this
system in diabetic nephropathy. The possibility of
therapeutic intervention targeting bradykinin and its
receptors as treatment for diabetic microvascular conditions
is considered.
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Diabetic retinopathy is a leading cause of vision loss in
working-age adults and this condition often occurs concur-
rently with diabetic nephropathy.1 A growing body of
evidence has implicated the kallikrein–kinin system (KKS)
in the pathogenesis of both these microvascular complica-
tions of diabetes mellitus. Bradykinin (1–9) and its receptors,
bradykinin receptors 1 (B1) and 2 (B2), are the primary
effector pathway of the KKS and have been reported to exert
both protective2–4 and adverse5,6 effects on the kidney.
Studies using B2 receptor-deficient mice with diabetes have
shown both increased3 and decreased6 glomerular injury
compared with diabetic wild-type controls. Recently, we have
reported that activation of plasma kallikrein in the vitreous
can increase retinal vascular permeability, and in the presence
of diabetes cause retinal edema.7 Indeed, bradykinin has been
shown to exert both proinflammatory and proangiogenic
effects that are central to the pathogenesis of sight-
threatening proliferative diabetic retinopathy (PDR) and
diabetic macular edema.
As the KKS may provide therapeutic targets for both
diabetic retinopathy and diabetic nephropathy, further
understanding of the actions of this system in the patho-
genesis of retinal and renal injury in diabetes is critical. We
review the role of the KKS in pathways that are fundamental
to the development of diabetic retinopathy, namely increased
vascular permeability, neovascularization, and inflammation,
and consider the possibility of therapeutic intervention
targeting plasma kallikrein and bradykinin receptors as
treatment for this condition.
THE KKS IS REGULATED AT MULTIPLE LEVELS
The actions of the KKS are primarily mediated by bradykinin
(1–9), a peptide hormone that exerts potent proinflammatory
and vasodilatory effects through the activation of two cell
surface G-protein-coupled receptors: B1 receptor and B2
receptor (Figure 1). The half-life of bradykinin in plasma is
short (27±10 s),8 suggesting that its actions are regulated
locally through its production and proteolytic processing
within tissues. The generation of bradykinin is mediated by
both plasma and tissue kallikreins, which are serine proteases
that differ in their distribution and regulation. Human tissue
kallikreins are a subgroup of 15 homologous secreted trypsin
or chymotrypsin-like serine proteases (hK1 to hK15) encoded
on chromosome 19q13.4.9 hK1 is the only member of the
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family that forms bradykinin and lys-bradykinin (kallidin)
through its cleavage by low-molecular-weight kininogen. The
production of bradykinin by tissue kallikrein is inhibited by
protease inhibitors, such as kallistatin9 (Figure 1).
Plasma kallikrein is encoded by a single gene localized on
human gene 4q35 and is synthesized primarily in the liver.
Plasma kallikrein is an abundant enzyme (35–50mg ml1) in
plasma, and its activity is acutely increased by contact with
negatively charged surfaces. This results in the cleavage of its
substrates, factor XII (FXII) to factor XIIa (FXIIa), initiating
the positive feedback mechanism of contact system activation,
and high-molecular-weight kininogen (HK), resulting in the
release of bradykinin (Figure 1). Although the physiological
mechanisms that activate plasma kallikrein are not fully
understood, we have recently demonstrated that plasma
kallikrein can also be activated by a modest increase in pH,
induced by extracellular carbonic anhydrase.7 The primary
physiological inhibitors of plasma kallikrein are complement
1 inhibitor (C1-INH) and a-2 macroglobulin.10 C1-INH is
also a primary physiological inhibitor of FXIIa, and thereby
an inhibitor of plasma kallikrein activation.
The relative contributions of plasma and tissue kallikrein
isoenzymes to bradykinin production and the downstream
consequences of bradykinin actions are likely different in the
retina and kidney. Although tissue kallikrein mRNA has been
detected in human retina,11 its role in retinal physiology is
unknown. Tissue kallikrein activity appears very low to
undetectable in vitreous of people with PDR.12 Intravitreal
injection of a tissue kallikrein inhibitor, kallistatin, in rats
with streptozotocin (STZ)-induced diabetes reduced retinal
neovascularization; however, these effects have been attrib-
uted to the effects on the VEGF system.13 In contrast, we have
recently demonstrated that vitreous fluid from people with
PDR contains contact system proteins, including plasma
kallikrein, FXII, and HK.7 These findings suggest that the
plasma kallikrein system could play an important role in
regulating the intraocular KKS in diabetic retinopathy. As
these contact system components are highly abundant in
the plasma, we have proposed that these proteins reach the
retinal interstitium and vitreous by crossing the blood–retinal
barrier through increased vascular permeability and retinal
hemorrhage, which are hallmarks of diabetic retinopathy
(Figure 2).
In the kidney, disruption of the tissue kallikrein (KlK1)
gene dramatically reduces renal kinin production,14 suggest-
ing that tissue kallikrein is the main bradykinin-generating
enzyme in the kidney. Little is known regarding the potential
role of plasma kallikrein and the contact system on renal
function and diabetic nephropathy. In diabetes, renal
kallikein levels and excretion of urinary kallikrein are
decreased.15 Although the intrarenal KKS has been impli-
cated in contributing to diabetic nephropathy,16 both
beneficial and detrimental actions of bradykinin have been
described.3,6
The downstream biological effects of the KKS are
primarily mediated by B2 and B1 receptors, which are widely
expressed in vascular tissues, including in the retina.11 The B2
receptor is constitutively expressed in many vascular and
neuronal tissues, whereas the B1 receptor is inducible and has
been attributed to many of the proinflammatory actions of
bradykinin.17,18 Activation of these receptors stimulate
potent vasoactive mediators, such as endothelial nitric oxide
synthase (eNOS), leading to the increased production of
nitric oxide (NO), cyclic GMP, and prostacyclin.19 Plasma
kallikrein has also been shown to mediate plasminogen
activation to plasmin,20 which mediates both fibrinolysis and
the activation of matrix metalloproteinases. These findings
Prekallikrein
FXIIa C1-INH
FXII
Plasma kallikrein C1-INHA2MKallistatin
Inactive fragments
Tissue kallikrein
(hK1)
Plasminogen
HKLK
ACE, NEP
ACE, NEP
[des-Arg9]-bradykinin
Kininase I 
Bradykinin (1–9)
Plasmin
Extracellular
proteolysis
HOE-140
B1-rec B2-rec
Figure 1 | The kallikrein–kinin system. The pathways involved in the
kallikrein–kinin and contact systems. A2M, a-2-macroglobulin; ACE,
angiotensin-converting enzyme; B1-rec, bradykinin 1 receptor; B2-rec,
bradykinin 2 receptor; C1-INH, complement 1 inhibitor; FXII, factor XII;
FXIIa, factor XIIa; HK, high-molecular-weight kininogen; LK, low-
molecular-weight kininogen; NEP, neural endopeptidase 24.11.
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Figure 2 | Potential interactions of the KKS in diabetic
retinopathy. Schematic of the retinal fundus illustrating the
potential involvement of the components of the KKS found in the
vitreous in diabetic retinopathy changes. Red lines indicate arteries
and blue lines indicate veins. FXII, factor XII; FXIIa, factor XIIa; HK,
high-molecular-weight kininogen; Kal, kallikrein; PK, prekallikrein;
KKS, kallikrein–kinin system.
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suggest that the KKS may exert effects on vascular home-
ostasis through bradykinin receptor-independent mechan-
isms. The consequences of these kallikrein and bradykinin
actions could have critical differences in regard to the
pathogenic mechanisms contributing to diabetic retinopathy
and nephropathy.
Bradykinin is rapidly metabolized by a number of
kininases, including the angiotensin-converting enzyme
(ACE), also known as kininase II, and neural endopeptidase
24.11, a kininase that is abundant in the kidney. Kininase
I-type carboxypeptidases convert bradykinin into [des-Arg9]-
bradykinin, which exerts its maximal effect through the B1
receptor.21 In acquired angioedema, ACE inhibition can
increase circulating concentrations of bradykinin,22 confirm-
ing the importance of ACE-mediated proteolysis in the KKS.
Indeed, the beneficial effects of ACE inhibitors have been
attributed to both the inhibition of angiotensin II production
and the reduction of bradykinin breakdown. Thus, bradyki-
nin concentrations and actions in the retina and kidney could
potentially be regulated at the level of bradykinin proteolysis.
PATHOGENESIS OF DIABETIC RETINOPATHY
Diabetic retinopathy is primarily considered a vascular
disease; however, involvement of the neuroretina is also
evident.23 The initial stages of diabetic retinopathy include
changes in blood flow and vessel diameters, as well as the
development of microaneurysms and retinal hemorrhages
(reviewed in Frank24). Microvascular changes, such as
basement membrane thickening, pericyte loss, leukostasis,
and increased retinal vascular permeability, also occur early
in the disease progression.25 The presence of increased
vascular permeability and leukostasis suggests that retinal
inflammation plays a role in the pathogenesis of diabetic
retinopathy, and indeed inflammatory changes are noted
early following the onset of diabetes in the vasculature of
insulin-deficient diabetic rats.26 Increased retinal vascular
permeability can progress and contribute to the development
of macular edema, one of the most common causes of vision
loss in diabetic retinopathy. The primary cause of macular
edema is thought to involve the breakdown of the blood–-
retinal barrier, causing leakage of plasma from small blood
vessels into the central portion of the retina and subsequent
intraretinal swelling.24 In addition, diabetic retinopathy can
cause areas of reduced vascular perfusion, which can lead to
retinal hypoxia and trigger neovascularization.24 This re-
sponse is one of the hallmarks of the most severe forms of the
disease, PDR, which can lead to vitreous hemorrhage, retinal
detachment, and severe vision loss.
THE ROLE OF THE KKS IN PATHWAYS CENTRAL TO THE
DEVELOPMENT OF DIABETIC RETINOPATHY
The KKS in vascular permeability and vasogenic edema
Our recent studies have shown that activation of the
intraocular KKS can increase retinal vascular permeability
in rats and, in the presence of diabetes, induce retinal edema.7
This study extends previous findings that have shown
antagonism of the B1 receptor ameliorates vascular leakage
in the retina in rats with STZ-induced diabetes.27 Moreover,
these results are consistent with a large body of evidence that
show bradykinin can increase vascular permeability, a
response that has been demonstrated in a number of tissues.
Indeed, bradykinin-induced vascular permeability is not a
newly described phenomenon and was first reported several
decades ago.28 Intravenous injections of bradykinin have
been shown to increase the extravasation of 100 nM micro-
spheres from tracheal venules in mice,29 giving an indication
of the magnitude of bradykinin’s effects on vascular
permeability. In an experimental stroke model, ischemia/
reperfusion injury induced by middle cerebral artery
occlusion has been shown to increase local tissue bradykinin
levels and B2 receptor expression, and cerebral edema
induced by this injury is reduced in B2 receptor knockout
mice compared with controls.30 Bradykinin also induces
leakage in postcapillary venules of rat mesentery through
a B2 receptor-dependent mechanism, involving protein
kinase C activation and cytochrome P450 epoxygenase.31 In
the retina, we have found that eNOS inhibition with N(G)-
nitro-L-arginine methyl ester (L-NAME) reduced retinal
vascular permeability.7 Bradykinin receptors have been
shown to activate eNOS,32 contributing to endothelium-
dependent vasorelaxation. Although this pathway is generally
considered vasoprotective, activation of eNOS can also
contribute to increased vascular permeability,33 which can
exert adverse effects in neurovascular tissues. These results
indicate that bradykinin may increase vascular permeability
through multiple mechanisms.
Mechanisms involving the KKS in retinal vascular
permeability may have parallels to the development of
angioedema. The bradykinin pathway has been associated
with both acquired and hereditary angioedema. Nussberger
et al.22 have shown that plasma bradykinin is elevated during
angioedema attacks and that infusion with a C1-INH
immediately lowers bradykinin levels. The involvement of
the bradykinin pathway in acquired angioedema mediates, at
least in part, the adverse effects of ACE inhibitors in this
condition.22 Han et al.34 demonstrated that B2 receptors are
required for angioedema in C1-INH null mice. These
findings suggest that C1-INH deficiency results in increased
plasma kallikrein and FXIIa activities, which increase
bradykinin production and promote B2 receptor-mediated
vasogenic edema. Collectively, these findings using animal
models suggest a pathway (plasma kallikrein-bradykinin-
B2-eNOS) contributing to vascular permeability and
edema. Moreover, recent clinical trials have shown that the
B2 receptor antagonist icatibant35 and the kallikrein inhibitor
ecallantide36 reduced symptoms in acute attacks of angioe-
dema. Although the role of plasma kallikrein and the KKS in
retinal vascular permeability in people with diabetic retino-
pathy is not yet available, the recent identification of plasma
kallikrein, FXII, and HK in the vitreous of individuals with
PDR7 suggests that this pathway may contribute to retinal
vascular permeability and edema in diabetic retinopathy.
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The role of the KKS in neovascularization
The development of new blood vessels is a hallmark of PDR.
Although the role of the KKS in retinal neovascularization is
not known, the proangiogenic effects of the KKS have been
demonstrated in other tissues.
The local delivery of bradykinin and B1 receptor-selective
agonists stimulates angiogenesis in rabbit cornea.37 More-
over, bradykinin also induces neovascularization in the
chicken chorioallantoic membrane assay.38 HK promotes
angiogenesis and may contribute to fibroblast growth factor 2
and vascular endothelial growth factor-induced angiogenesis
through its cleavage by kallikrein to release bradykinin.38
A neutralizing antibody against the light chain of HK, which
interferes with the binding of HK to endothelial cells and
thus blocks the cleavage of prekallikrein to kallikrein, inhibits
tumor angiogenesis in a murine xenograft model.39 In
models of angiogenesis induced by hind limb ischemia, the
knockout of B1 receptor has been shown to impair new vessel
growth, whereas a B1 receptor agonist increased the amount
of neovascularization.40 In addition, the B2 receptor has also
been implicated in angiogenesis.41 These results suggest
that the KKS contributes to ischemia-induced angiogenic
responses.
A limited number of studies suggest that the angiogenic
response could be mediated by the upregulation of
proangiogenic factors such as fibroblast growth factor 237
and through transactivation of the vascular endothelial
growth factor-receptor 2 (Flk-1, KDR).32 Although evidence
for the direct activation of the vascular endothelial growth
factor pathway by bradykinin in vivo is not yet available,
therapeutic intervention targeting new blood vessel growth
by modulating bradykinin action is intriguing.
The involvement of the KKS in inflammatory pathways
Retinal inflammation is involved in the development of
diabetic retinopathy, with not only increases in vascular
permeability, but also increases in leukostasis, superoxide,
nuclear factor-kB, NO, cyclooxygenase 2, and prostaglandin-
E2 seen in diabetic rat retinal microvessels.26 Treatment of
diabetic rats with topical nepafenac has been shown to
ameliorate retinal inflammation and microvascular abnorm-
alities, suggesting that these inflammatory pathways con-
tribute to the pathogenesis of diabetic retinopathy.26
Activation of the KKS has been shown to induce a host of
proinflammatory responses. It has been reported that the B1
receptor expression is increased in the retina of rats with
STZ-induced diabetes42 and that the activation of nuclear
factor-kB upregulates B1 receptor expression.18 Bradykinin
has also been demonstrated to cause leukostasis,31,43 possibly
through a mechanism that involves bradykinin-induced
superoxide formation.31 Moreover, proinflammatory cyto-
kines can upregulate the B1 receptor.44 Expression of the B1
receptor is increased in lipopolysaccaride-induced vascular
smooth muscle cells through a nuclear factor-kB-like nuclear
factor.44 An absence of B1 receptors results in decreased
inflammatory responses to lipopolysaccaride, including a
decrease in leukostasis,45 and mice overexpressing the B1
receptor display increased susceptibility to paw edema,46
confirming that this receptor plays a central role in the
initiation and modulation of inflammation. As the KKS is
present in the vitreous from people with PDR, the
proinflammatory effects of bradykinin and its receptors
may contribute to retinal inflammation.
THE KKS IN DIABETIC RETINOPATHY: LESSONS FOR THE
KIDNEY
The KKS, through activation of both B1 and B2 receptors,
exerts a plethora of actions on vascular and neuronal tissues.
In the eye, we have shown that the plasma KKS is present in
the human vitreous from people with PDR and that this
system can contribute to increased retinal vascular perme-
ability in rodent models.7 These findings are consistent with
the well-documented effects of the KKS in vasogenic
edema.22,34 Moreover, the KKS has been reported to
contribute to angiogenesis and inflammation in a variety of
tissues, suggesting that this system may also contribute to the
proliferative ocular complications of diabetes. On the basis of
these findings, the plasma KKS might provide a therapeutic
target for diabetic macular edema and PDR.
In diabetic nephropathy in mice, both beneficial and
adverse effects of B2 receptor deficiency have been reported.
B2 receptor deficiency has been shown to increase albumin
excretion and glomerular mesangial sclerosis in mice with
diabetes caused by the Akita mutation, Ins2þ /C96Y.3 In
contrast, Tan et al.6 recently demonstrated that deletion of
the B2 receptor decreases glomerular and tubular injury and
albumin excretion in mice made diabetic with STZ.
A number of factors may contribute to the apparent
differences in the role of the B2 receptor in diabetic
nephropathy described in these reports, including differences
in background genetics and the specific end points measured.
Both studies, however, showed an increase in B1 receptor
expression in diabetic B2 receptor knockouts, increased
by approximately 10- and 25-fold in STZ diabetes and
Akita-induced diabetes, respectively. At this time, it is not
known whether B2 receptor deficiency selectively affects the
B1 receptor or whether the absence of B2 receptors is
associated with other expression abnormalities apart from
the B1 receptor. Kakoki et al.4 demonstrated that ischemia/
reperfusion injury in mice deficient in both B1 and B2
receptors was worse than that observed in either B2 receptor-
deficient or wild-type mice, demonstrating that both B1 and
B2 receptors can affect ischemia/reperfusion injury. The
protective effects of B1 and B2 receptor deficiency seem to
contrast the results, demonstrating that stimulation of the B2
receptor by pretreatment with kallikrein worsens renal
dysfunction in ischemia/reperfusion injury.5 However, as
both complete bradykinin receptor deficiency and over-
activation of bradykinin receptors could potentially exert
adverse effects, additional information is needed to identify
the role and mechanisms of bradykinin action that are
associated with the susceptibility to renal injury induced by
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diabetes or ischemia/reperfusion. On the basis of the findings
of the KKS role in diabetic retinopathy, the potential effects
of bradykinin on vascular permeability in the kidney warrant
consideration.
These results from both diabetic retinopathy and diabetic
nephropathy indicate that the KKS plays a role in the
microvascular complications of diabetes. Evaluation of the
KKS as a potential therapeutic target for these complications
will require additional information regarding the actions of
specific kallikrein type (hK1 vs plasma kallikrein) and
bradykinin receptors (B1 vs B2) on both the vascular
functional abnormalities and histological changes associated
with the pathogenesis of these conditions. Moreover,
further understanding of the effects of bradykinin receptor-
stimulated vasoactive substances, such as those of NO on
intraglomerular pressure and retinal vascular permeability,
will also need to be taken into consideration. Therefore,
although components of the KKS might provide therapeutic
targets for both diabetic retinopathy and diabetic nephro-
pathy, further understanding of the systemic actions of this
system is critical.
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